

## PROFFERED ABSTRACTS

**Sunday, July 19, 2026, 6:30-7:30 p.m.**

PR001 B010 **The CCDI-COG Molecular Characterization Initiative (MCI) in rare pediatric cancers**, Kenneth S. Chen, UT Southwestern, Dallas, TX, USA


PR002 B001 **Breaking Barriers in Rare Cancer Research: Patient-Partnered Research via Social Media as a Model for Generating Evidence in Granulosa Cell Tumor of the Ovary**, Simon Chu, Hudson Institute of Medical Research, Clayton, Victoria, Australia

PR003 B012 **Clonally inherited bivalent chromatin states in SS18::SSX-associated synovial sarcoma**, Jakob Hofvander, Lund University, Lund, Sweden

PR004 B009 **A comprehensive pan-sarcoma single-cell transcriptomic meta-analysis reveals shared molecular programs across subtypes**, Maria Korah, Stanford University, Palo Alto, CA, United States

PR005 B013 **Conditional Reprogramming Enables Rapid Establishment of Patient-Derived Neuroendocrine Tumor Models for Functional Precision Oncology**, Xuefeng Liu, The Ohio State University, Columbus, OH, United States

PR006 B011 **Target discovery in rare cancers enabled by transcriptome-based virtual CRISPR screening**, Srinivas Viswanathan, Dana-Farber Cancer Institute, Boston, MA, United States



**POSTER SESSION A**  
**Saturday, July 18, 2026, 7:30-9:30 p.m.**

**A002 Bcl-2–Dependent Apoptotic Resistance Overcome by (2-Methylbutyryl) Shikonin Through ROS-Driven Mitochondrial Signaling in Melanoma**, AALIM BHAT, CSIR-Indian Institute of Integrative Medicine Jammu- 180001, Jammu, India

**A003 Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene**, Manole Cojocaru, Titu Maiorescu University of Bucharest, Faculty of Medicine, Romanian Academy of Scientists, Bucharest, Romania

**A004 Voltage and calcium dynamics determine Tir-induced pyroptosis in triple-negative breast cancer cells**, Polly Dean, Institute of Cancer Research, London, United Kingdom

**A005 Investigating the role of stabilin-2. in hematopoietic stem and progenitor cell emergence and migration in zebrafish**, Reema Elrefaie, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States


**A006 SHMT2 is a novel protein target in the rare malignancy Spindle epithelial tumor with thymus-like elements (SETTLE).**, Verena Goebeler, University of British Columbia, VANCOUVER, BC, Canada

**A007 Hsp27 Mediates Sensitivity to Gemcitabine through Mitophagy Regulation in Osteosarcoma**, Nancy Gordon, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**A008 The anti-diabetic drug Pramlintide modulates osteosarcoma tumor metabolism and improves NK cell therapy**, Nancy Gordon, UT MD Anderson Cancer Center, Houston, TX, United States

**A009 Integrating HER2-Targeted Antibody-Drug Conjugates into Mucinous Ovarian Cancer Treatment: A Preclinical Assessment**, Irina Gorobets, Peter MacCallum Cancer Center, Melbourne, VIC, Australia

**A010 Dual estrogen receptor and PKC $\beta$  signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune–Albright Syndrome**, Sandra Hammer, Atossa Therapeutics Inc, Seattle, WA, United States



**A011 Leveraging a High-Throughput 2D Invasin-Based Organoid Platform for Precision Oncology and Clinical Correlation in Small Bowel Adenocarcinoma**, Ya'an Kang, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**A012 Subcutaneous ANtibody-conjugated microGel platform enabling combination immunotherapy for refractory solid tumors**, Jongseong Kim, OncoLab co. Ltd., Goyang, Korea, Rep.

**A013 Prolonged survival in unresectable primary squamous cell carcinoma of the pancreas treated with multimodal therapy despite absence of actionable genomic drivers**, Lauren King, Penn State Milton S Hershey Medical Center, Hershey, PA, United States

**A014 Targeting shared metabolic vulnerabilities in IDH-mutant gliomas and colorectal cancer: a new therapeutic angle for rare brain tumors**, Lei Li, Shaanxi University of Chinese Medicine, Xianyang, China

**A015 Targeting polyamine metabolism to overcome PARP inhibitor resistance in Colorectal Cancer**, Eman Masood, Carnegie Mellon University Qatar, Doha, , Qatar

**A016 Single-nuclear RNA sequencing of retroperitoneal liposarcoma reveals progenitor cells of dedifferentiated liposarcoma in well-differentiated liposarcoma**, James Agolia, Stanford University, Stanford, CA, United States


**A017 FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma**, Frank McKeon, Wake Forest University, Charlotte, NC, United States

**A018 Identifying potential cell-surface targets for therapeutic treatment of DICER1.-related cancers**, Brenya McNally, Children's Minnesota, Minneapolis, MN, United States

**A019 Immunohistochemical evaluation of membrane surface targets B7-H3 (CD276), PTK7, IL1RAP, ROR1, AQP4, and LRRC15 in pediatric, adolescent and young adult sarcomas**, Soroush Mohebat, The University of British Columbia, Vancouver, BC, Canada

**A020 Diagnostic and therapeutic challenges of squamous cell carcinoma of the prostate**, Chidi Molokwu, Bradford Teaching Hospitals NHS Trust, Bradford, , United Kingdom

**A021 Surface and global proteome profiling identifies ROR2 and other surface proteins as actionable immunotherapy targets in osteosarcoma**, Brian Mooney, BC Cancer Research Center, Vancouver, BC, Canada



A022 **Uncovering CAR-T targets from the cholangiocarcinoma proteome**, Gregg Morin, BC Cancer Research Institute, Vancouver, BC, Canada

A023 **Inhibition of GPR68 induces ferroptosis in diffuse intrinsic pontine gliomas**, Leif Neitzel, Michigan State University, East Lansing, MI, United States

A024 **LP-184, a novel acylfulvene alkylating agent, demonstrates potent antitumor activity and survival benefit in SMARCB1-deficient tumor models**, Nisha Shah, Johns Hopkins, Baltimore, MD, United States

A025 **Dual NR4A1/2 ligands inhibit PAX3-FOXO1 and promote ferroptosis in Rhabdomyosarcoma**, Arafat Rahman Oany, Texas A&M University, College Station, TX, United States

A026 **AI-Enabled Digital Pathology and Multi-Omics Integration for Cell-Type-Resolved Biomarker Discovery in Environment-Associated Cancers**, Sandeep Singhal, University of North Dakota, Grand Forks, ND, United States

A027 **Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development**, Sanjana Srinivasan, The University of Texas MD Anderson Cancer Center, Houston, TX, United States


A028 **mirAI: Computational prioritization of allele-selective synthetic microRNAs for KRAS G12D-driven cancers**, Ahaan Thota, Dulles High School, Sugar Land, TX, United States

A029 **Durvalumab and tremelimumab in patients with metastatic non-adenoid cystic salivary gland cancer treated in the CCTG IND.228 phase II basket trial**, Eric Winquist, Verspeeten Family Cancer Centre, London, ON, Canada

A030 **Functional precision medicine targeting polyresistant cancer stem cells in high-grade serous ovarian cancer**, Wa Xian, Wake Forest University, Charlotte, NC, United States

A031 **Pre-diagnostic clinical-trajectory signatures of early-onset pancreatic cancer**, Yan Bi, Mayo Clinic, Jacksonville, FL, United States

A032 **Disseminated malignant granular cell tumor with multiorgan metastases and PD-L1-negative phenotype: A translational case of an ultra-rare Schwann-cell neoplasm**, Randa Elzein, Upstate University Hospital, Syracuse, NY, United States



**A033 Integrated PET/CT Phenotyping with Novel Hotspot-Weighted Uptake and Spatial Hotspot Descriptors for Risk Stratification in Malignant Pleural Mesothelioma**, Dr Nitin Gupta, Dr Rajendra Prasad Government medical college and hospital, Kangra, , India

**A034 Integrated multi-omics analysis of uterine mesonephric-like adenocarcinoma identifies novel diagnostic and therapeutic targets**, Zahra Mohammadi, University of British Columbia (UBC), Vancouver, BC, Canada

**A035 Integrated Molecular Subtypes and Hormone Receptor Status Improve Outcome Prediction in Rare Ovarian Cancer: Results from the Multi-National Endometrioid Ovarian Cancer (MECC) Study**, Bianca Ribeiro de Souza, University of British Columbia, Vancouver, BC, Canada

**A036 Risk stratification of females with diabetes mellitus: A-to-I editing of GABRA3 under ADAR-1 mediated activity in pancreatic ductal adenocarcinoma**, Brittany Wells, Arizona State University, Tempe, AZ, United States


**A037 Molecular characterization of adult small round blue cell tumors reveals frequent non-classical EWSR1 and related rearrangements**, Samer Yassin, Northwestern University Feinberg School of Medicine, Chicago, IL, United States

**A038 Multi-omics and Mendelian randomization analyses reveal a COLEC11. gene-metabolite-microbiota axis in imatinib-resistant gastrointestinal stromal tumors**, Xuhui Bao, Center for Clinical Research, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China


**A039 Goblet Cell Appendiceal Adenocarcinoma is A Distinct Disease Entity Defined by LGR5/Wnt mediated oncogenesis driving an Immune-Excluded Tumor Microenvironment**, Sacha El Khoury, The University of Texas MD Anderson, Houston, TX, United States

**A040 Microphysiological models uncover invasive and proteomic shifts in Ewing sarcoma cell subpopulations**, Neica Joseph, Rice University, Houston, TX, United States

**A041 Comparative analysis of tertiary lymphoid structures in canine osteosarcoma supports cross-species tumor immunity in a rare malignancy**, Amy LeBlanc, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States



- A042 A unified computational framework for 3D spatial transcriptomics reconstruction and its application to hereditary diffuse gastric cancer**, Ziyi Li, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- A043 Paracrine remodeling of normal fibroblasts into glioblastoma-associated states: An immune-enriched stromal model of GBM**, Mahdiah Shokrollahi Barough, University of Victoria, Victoria, BC, Canada
- A044 Dissecting the developmental trajectory of DICER1 syndrome-associated sarcoma with genetically engineered mouse models**, Yemin Wang, University of British Columbia, Vancouver, BC, Canada
- A045 Clinical benefit of MAPK inhibition in appendiceal adenocarcinoma**, Somer Abdelfattah, Memorial Sloan Kettering, Somerset, NJ, United States
- A046 Precision Medicine and Ultra-Rare Cancers: Genomic Insights from a Private Hospital Experience**, Sourat Darabi, Hoag Family Cancer Institute, Newport Beach, CA, United States
- A047 A novel and L2086F resistance overcoming type II ROS1/NTRK inhibitor ANS03 in heavily pretreated NSCLC patients with ROS1 fusion**, Alexander Drilon, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, NY, USA, New York, NY, United States
- A048 Decoding tumor seeding in retinoblastoma: The genomic clues from aqueous humor liquid biopsy**, Nerea Goni, Children's Hospital Los Angeles, Los Angeles, CA, United States
- A049 Bap1-driven soft tissue sarcomas: Mouse modeling and therapeutic strategies**, Jianguo Huang, Providence Cancer Institute, Portland, OR, United States
- A050 The top functional driver of brain metastasis carries zero somatic mutations in 1,879 patients: class-aware multi-modal integration exposes the blind spot in sequencing-based target discovery**, Fahad Kiani, CrisPRO.ai, Brooklyn, NY, United States
- A051 Mechanistic synthetic lethality therapy ranking from tumor mutations: A deterministic sequence-pathway floor with evidence augmentation and lineage-aware dependency grounding.**, Fahad Kiani, CrisPRO.ai, Brooklyn, NY, United States



**A052 Genomic landscape and survival outcomes in breast neuroendocrine carcinoma: A descriptive institutional cohort analysis**, Elyse Lopez, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**A053 Specific cancer cell and immune features mediate atezolizumab-regimen clinical benefit in anaplastic thyroid cancer (ATC) independent of BRAF or RAS oncogenic status**, Scott Woodman, University of Texas, MD Anderson Cancer Center, Houston, TX, United States

**A054 Convergent tumor microenvironment correlates of pembrolizumab response and resistance in advanced rare cancers**, Scott Woodman, University of Texas, MD Anderson Cancer Center, Houston, TX, United States


**A055 Integrative epigenomic characterization of MGMT and LINE-1 methylation in diffuse gliomas and colorectal cancer: insights from rare brain tumors**, Jinyu Lu, Shaanxi University of Chinese Medicine, Xianyang, China

**A056 From Driver Mutations to Liquid Biomarkers: A Bespoke dPCR Platform for Detecting Uveal Melanoma Circulating Tumor DNA**, Karan Mehta, University of Texas Southwestern Medical Center, Dallas, TX, United States

**A057 Advanced preclinical modeling enables comprehensive characterization of cardiac angiosarcoma biology.**, Rosalba Minelli, The University of Texas - MD Anderson Cancer Center, Houston, TX, United States

**A058 Genomic Profiling Identifies 19q13 Amplification in Sarcomatoid Bladder Carcinoma**, George Morris, Hunter College High School, New York, NY, United States

**A059 MCHR-1 as an emerging immunotherapy target in ovarian clear cell carcinoma: Opportunities and challenges for translational CAR-T development**, Vahid Vahedian, Faculty of Medicine, University of São Paulo, São Paulo, Brazil



## POSTER SESSION B

**Sunday, July 19, 2026, 7:30-9:30 p.m.**

**B001 Breaking Barriers in Rare Cancer Research: Patient-Partnered Research via Social Media as a Model for Generating Evidence in Granulosa Cell Tumor of the Ovary**, Simon Chu, Hudson Institute of Medical Research, Clayton, Victoria, Australia

**B002 From delayed diagnosis to advocacy: A patient-led approach to addressing equity gaps in rare cancer care**, Harjeet Kaur, Chai and Hope / Independent Patient Advocate, Calgary, AB, Canada

**B003 Inflammatory Breast Cancer in Canada: Patient perspectives on diagnostic delays, care gaps, and the need for change**, Michelle Nicholas, Inflammatory Breast Cancer Network Foundation Canada, Vancouver, BC, Canada

**B004 Rare oncogene driven lung cancer treatment access gap in Canada: A call for equitable, patient-centred care for rare cancers**, Tahsin Hassan Rahit, University of Calgary, Calgary, AB, Canada

**B005 A patient-centered approach to rare cancer research and biobanking**, Kristi Schurman, Fred Hutchinson Cancer Center, Seattle, WA, United States


**B006 Alliance for Rare Cancers: uniting to accelerate progress across rare cancers.**, Erin Siegel, PhD, MPH, Alliance for Rare Cancers, Rockville, MD, United States

**B007 Advocate Engagement Drives Research Priorities in Fanconi Anemia**, Isis Sroka, Fanconi Cancer Foundation, Eugene, OR, United States

**B008 A trend and ethical analysis of rare pediatric cancer research funding priorities; why certain pediatric cancers receive more research funding than others.**, Akua Williams, Washington University, St. Louis, MO, United States

**B009 A comprehensive pan-sarcoma single-cell transcriptomic meta-analysis reveals shared molecular programs across subtypes.**, Maria Korah, Stanford University, Palo Alto, CA, United States

**B010 The CCDI-COG Molecular Characterization Initiative (MCI) in rare pediatric cancers**, Kenneth Chen, UT Southwestern, Dallas, TX, United States



**B011 Target discovery in rare cancers enabled by transcriptome-based virtual CRISPR screening**, Srinivas Viswanathan, Dana-Farber Cancer Institute, Boston, MA, United States

**B012 Clonally inherited bivalent chromatin states in SS18::SSX-associated synovial sarcoma**, Jakob Hofvander, Lund University, Lund, Sweden

**B013 Conditional Reprogramming Enables Rapid Establishment of Patient-Derived Neuroendocrine Tumor Models for Functional Precision Oncology**, Xuefeng Liu, The Ohio State University, Columbus, OH, United States

**B014 Molecular Determinants of Metastatic Melanoma and Repurposed Drugs: A Pathway to Novel Therapeutic Strategies**, Ahad Nazir, RMI, Peshawar, KS, Pakistan

**B015 Clinical-stage ADC target enrichment across angiosarcoma anatomical subsets**, Corrie Painter, Angiosarcoma Awareness, Portland, ME, United States

**B017 TLR4 loss and IKK $\alpha$  haploinsufficiency drive bacterial dysbiosis and IL-4R-mediated squamous carcinogenesis in skin 3D organoids**, Amit Kumar Singh, NCI, NIH, Frederick, MD, United States

**B018 TLR4 Deficiency Drives Microbiota-Dependent IL-4R Signaling to Promote Squamous Cell Carcinogenesis**, Amit Singh, NCI, NIH, Frederick, MD, United States


**B019 Remarkable driver-gene homogeneity in squamous cell carcinoma arising in patients with recessive dystrophic epidermolysis bullosa**, Andrew South, University of Wisconsin-Madison, MADISON, WI, United States

**B020 Evaluating copy number changes of chromosomally unstable vulvar squamous cell carcinoma and vulvar intraepithelial neoplasia lesions**, Ramlogan Sowamber, BC Cancer Research Centre, Vancouver, BC, Canada

**B021 Autoimmunity versus apoptosis in some cases of chronic lymphocytic leukemia**, Aurelian Udristoiu, Titu Maiorescu University of Bucharest, Faculty of Medical Assistance-Targu Jiu, County Gorj, Targu Jiu, Romania

**B022 A Living Biobank and Functional Precision Oncology Platform for Rare Cancers**, Songli Zhu, Fred Hutchinson Cancer Center, Seattle, WA, United States

**B023 Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune**



**checkpoint inhibitor (ICI) treatment**, Florentia Dimitriou, University Hospital of Bern, Bern, Switzerland

**B024 Immune checkpoint blockade (ICB) in advanced/metastatic leiomyosarcoma (LMS): Real-world cohort from MD Anderson.**, Nassar El Assaad, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**B025 Early PD-1 signaling drives mitochondrial stress and functional suppression in T-cells in B-cell Lymphoma**, Yan Feng, Western University of Ontario, London, ON, Canada

**B026 RB1 loss is associated with greater PD-1:PD-L1 interaction in Pulmonary Large Cell Neuroendocrine Carcinoma**, Jihyun Lee, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

**B027 RB1 Loss in Pulmonary Large Cell Neuroendocrine Carcinoma is Associated with More Abundant Pro-inflammatory Stromal Immune Cells**, Michael Minkley, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada


**B028 Repurposing adult clinical trials for rare cancer immune target discovery using the CURE AI foundation model**, Neil Pfister, Numenos, University of Alabama at Birmingham, New York, NY, United States

**B029 Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas – results**, Artemii Rynda, Russian Neurosurgical Institute named after prof. A.L. Polenov – a branch of the National Medical Research Center named after V.A. Almazov Ministry of Health of Russia, Saint-Petersburg, , Russian Federation

**B030 BRAF Treatment Response Determinants in Anaplastic Thyroid Cancer Studied Through Single Cell DNA and RNA Sequencing.**, Jennifer Wang, MD Anderson Cancer Center, Houston, TX, United States

**B031 Pan-cancer dissection of TERT promoter mutations in rare gliomas and colorectal cancer: shared vulnerabilities and therapeutic implications**, Jinyu Lu, Shaanxi University of Chinese Medicine, Xianyang, China

**B032 Harnessing anti-EGFR immunotherapy in glioblastoma: lessons from the immune microenvironment of colorectal cancer**, Jinyu Lu, Shaanxi University of Chinese Medicine, Xianyang, China



**B033 IL1RAP ADCs potently target primary and metastatic disease in multiple oncofusion-driven cancers**, Hai-Feng Zhang, BC Cancer Research Institute, Vancouver, BC, Canada

**B034 Radical collaboration in rare oncology: Accelerating therapeutic validation through federated learning and remote precision master protocols**, Debanjan Gangopadhyay, Brainware University, Barasat, India

**B035 A Phase 2 Platform Trial Integrated with Patient Digital Twins to Prioritize and Refine Therapies for Sarcomas: The RAPID Study**, Joseph Ludwig, MD Anderson Cancer Center, Houston, TX, United States

**B036 The Rare Ovarian Cancer Collaborative Analytics (ROCCA) platform: Advancing research through a federated data network**, Aline Talhouk, University of British Columbia, Vancouver, BC, Canada

**B037 Patient-derived organoid biobank of glioblastoma and colorectal cancer for functional**, Lei Li, Shaanxi University of Chinese Medicine, Xianyang, China


**B038 Multi-omic Analyses in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp**, Hannah Beird, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**B039 Genomic and epigenomic complexity underlies barrett's esophagus progression to adenocarcinoma**, Shilpa Dhar, UT MD Anderson Cancer Center, Houston, TX, United States

**B040 Bridging epigenetic mechanisms in brain cancer: A perspective on the interventions of creative arts therapy on patient outcomes**, MD Noushad Javed, Centre of Excellence in Nanotechnology, UTRGV, Edinburg, TX, United States

**B041 5-Base cfDNA Fragmentomics Reveals Cancer-Associated Alterations in Gallbladder Cancer**, Jill Koshiol, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, Rockville, MD, United States

**B042 A differentiation-driven migration program in rhabdomyosarcoma (RMS) is governed by a BRD1-MYOG transcriptional axis**, Andrea Largent, University of Washington, Seattle, WA, United States



**B043 Microenvironmental stress programs polyploid giant cancer cell lineages that generate resistant progeny: implications for rare aggressive cancers**, Sungsu Park, Sungkyunkwan University, Suwon, Korea, Rep.

**B044 Patient-driven N-of-1 Longitudinal Multi-Omic Study of Uveal Melanoma Identifies Functional Loss of BAP1 VUS and Evolving Tumor-Immune Dynamics**, Marshall Thompson, Rare Cancer Research Foundation, Durham, NC, United States

**B045 The Efficacy and Safety of Asciminib in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis**, Muh'd Saheed Abd-Rouf, New Mexico Highlands University, Las Vegas, NM, United States

**B046 Visualizing viral evasion of PRRs: A review of live cell imaging and confocal microscopy techniques**, Zainab Adenekan, Georgia State University, Atlanta, GA, United States


**B047 Managing Suspected Leptomeningeal and Multifocal Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach in a Guideline Gray Zone**, Emmanuel Agyemang, Newark Beth Israel Medical Center, Palmetto, GA, United States

**B048 Nasser's Express Insertion Technique (NEIT): A Simplified and Effective Approach to Cervical Cancer Intracavitary Brachytherapy Without Anesthesia for Resource-Limited Settings, Operational Disruptions, and Patients Unfit for Anesthesia.**, Nasser Al-Dhaibani, King Abdullah Medical City, Makkah, Saudi Arabia

**B049 Rare Melanoma Translational Core: A patient-guided platform for acral and mucosal melanoma PDX model generation, characterization, and distribution.**, Stacey Bagby, CU Anschutz Medical Campus, Aurora, CO, United States

**B051 Keratin K6/K14 Fusion Expands Non-Genetic Phenotypic State Space to Drive Cell Fusion, Aggressiveness, and Immune Modulation in Oral Squamous Cell Carcinoma**, Preetham Boominathan, National Sun Yat-sen University, Kaohsiung City, Taiwan

**B050 Deciphering Rare Patterns of Dual Drug Resistance in metastatic castration resistant prostate cancer through Machine Learning-Based ctDNA Methylation and CTC Transcriptomics**, Jae-Seung Chung, Haeundae Paik Hospital, Inje University, Busan, Korea, Rep.



**B052 The MRA Melanoma Biorepository: A centralized, broadly accessible resource for rare acral and mucosal melanoma research**, Kasey Coutts, University of Colorado Anschutz Medical Campus, Aurora, CO, United States

**B053 A randomized controlled trial for hereditary cancer in the cfDNA in Hereditary And High-Risk Malignancies (CHARM) consortium: Neurofibromatosis type 1 cohort**, Kirsten Farncombe, University Health Network, Toronto, ON, Canada

**B054 Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor**, Thanh Ho, Mayo Clinic, Rochester, MN, United States

**B055 A Genome-to-Vaccine: An Integrated Deep learning-Driven Neoantigen Identification and Multi-Epitope Vaccine Construction for Personalized Melanoma Immunotherapy**, Saba Ismail, university of Alberta, Edmonton, AB, Canada

**B056 Intrinsically disordered AF1 domain of glucocorticoid receptor as a novel potential target for triple negative breast cancer**, Shagufta Khan, Geisinger, Scranton, PA, United States

**B057 Clinical utility and in vitro anti-proliferative activity of a tissue-agnostic multi-target formula (WD-3) in rare malignancies**, Xiaodan Zhu, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China